Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108408 - CRYSTALLINE FORM OF LAROTRECTINIB HYDROGEN SULFATE SALT, PREPARATION METHOD THEREFOR AND USE THEREOF

Publication Number WO/2020/108408
Publication Date 04.06.2020
International Application No. PCT/CN2019/120340
International Filing Date 22.11.2019
IPC
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07B 2200/13
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
13Crystalline forms, e.g. polymorphs
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • 安礼特(上海)医药科技有限公司 ARIZEST (SHANGHAI) PHARMATECH CO., LTD. [CN]/[CN]
  • 江苏创诺制药有限公司 JIANGSU ACEBRIGHT PHARMACEUTICALS CO., LTD. [CN]/[CN]
  • 上海创诺医药集团有限公司 SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD. [CN]/[CN]
Inventors
  • 彭欢 PENG, Huan
  • 张良 ZHANG, Liang
Agents
  • 上海一平知识产权代理有限公司 XU & PARTNERS, LLC.
Priority Data
201811435351.X28.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) CRYSTALLINE FORM OF LAROTRECTINIB HYDROGEN SULFATE SALT, PREPARATION METHOD THEREFOR AND USE THEREOF
(FR) FORME CRISTALLINE DU SEL DE SULFATE D'HYDROGÈNE DE LAROTRECTINIB, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 拉洛替尼硫酸氢盐晶型及其制备和应用
Abstract
(EN)
The present invention relates to a crystalline form of Larotrectinib hydrogen sulfate salt and a preparation method therefor and a use thereof. In particular, the crystalline form of Larotrectinib hydrogen sulfate salt disclosed in the present invention has excellent solubility, stable mechanical properties and stability under high humidity conditions.
(FR)
La présente invention concerne une forme cristalline du sel de sulfate d'hydrogène de Larotrectinib, son procédé de préparation et son utilisation. En particulier, la forme cristalline du sel de sulfate d'hydrogène de Larotrectinib fournie par la présente invention a une excellente solubilité, des propriétés mécaniques stables et une stabilité dans des conditions d'humidité élevée.
(ZH)
本发明涉及拉洛替尼硫酸氢盐晶型及其制备和应用。具体地,本发明公开了拉洛替尼硫酸氢盐晶型,所述晶型具有优异的溶解性能、机械稳定性能和高湿稳定性。
Also published as
Latest bibliographic data on file with the International Bureau